Introduction: Turoctocog alfa pegol (N8-GP) is a site-specific, 40 kDa glycoPEGylated recombinant factor VIII (FVIII) product with an extended half-life. The comprehensive main phase of the pivotal pathfinder 2 trial showed N8-GP dosed every 4 days (Q4D) provided favourable safety and efficacy for preventing bleeds in 175 patients with haemophilia A.
Aim and methods:
We investigated the safety and efficacy of N8-GP prophylaxis when administered weekly (Q7D) for 24 weeks to patients with low bleeding rates in the pathfinder 2 extension trial. Patients (≥12 years) with ≤2 bleeds during the preceding 6 months of the pathfinder 2 main phase were eligible for randomization to receive N8-GP 50 IU/kg Q4D or 75 IU/kg Q7D. Safety and efficacy endpoints were incidence of FVIII inhibitors and annualized bleeding rate (ABR), respectively.
| INTRODUC TI ON
Although prophylaxis with factor VIII (FVIII) is widely considered to be the standard of care for patients with severe haemophilia A, [1] [2] [3] [4] [5] [6] barriers to its widespread implementation remain. 2, 6 A key barrier is the need for frequent injections (3-4 times/wk, translating to ~182 injections/y) due to the relatively short plasma half-life of standard FVIII products. 1, 3, [7] [8] [9] [10] Many patients struggle to integrate prophylactic schedules into their daily lives, leading to missed injections 8 and increased bleeding episodes. 2, 5 Therefore, prophylactic strategies offering effective haemostatic coverage with more convenient administration schedules are needed.
FVIII replacement therapy used to treat acute breakthrough bleeding episodes can also be problematic as multiple injections may be required over several days. 3, 11 Limitations of standard recombinant FVIII (rFVIII) products have driven improvements in both prophylactic and on-demand treatment for patients with severe haemophilia A. 4, 7, 12 Prolonging the FVIII circulation time has been a primary objective, 13 and several strategies have been developed. 9, [14] [15] [16] [17] N8-GP (turoctocog alfa pegol; Novo Nordisk, Bagsvaerd, Denmark) is a novel, extended half-life (EHL) rFVIII product produced by a site-specific 40 kDa glycoPEGylation of turoctocog alfa, a B-domain-truncated rFVIII. 9, 14 N8-GP has a half-life of 19 hours, corresponding to a 1.6-fold prolongation compared to patients' previous plasma-derived or standard rFVIII products. 9 In the main phase of the comprehensive, phase III pathfinder 2 trial, 14 N8-GP provided effective prophylaxis and maintained a low observed median annualized bleeding rate (ABR) of 1.18 when dosed every 4 days (Q4D) in 175 patients over 299 days (mean duration).
N8-GP was also effective for treating bleeding episodes (83.6% were resolved with a single injection and 95.5% with up to two injections). 14 In pathfinder 2, the main phase was followed by a two-part extension phase. The main objective of pathfinder 2 extension phase part 1 was to investigate the safety and efficacy of N8-GP for prophylaxis and treatment of bleeds when administered Q4D vs weekly (Q7D) to a randomized subset of patients who had low bleeding rates in the trial's main phase (≤2 bleeds in the last 6 months of the main phase). The extension phase provided an opportunity to explore whether selected patients could be managed with a once-weekly prophylactic schedule, while retaining the favourable safety and efficacy profile of N8-GP and reducing the treatment burden to 52 injections/y. Here, we report the findings from the pathfinder 2 extension phase part 1.
| TRIAL DE S I G N , PATIENTS , OBJEC TIVE S AND ENDP OINTS
Details of pathfinder 2 have been previously published, 14 but are described briefly here.
| Trial design
The trial was conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice guidelines, 18 the Declaration of Helsinki 19 and all applicable regulatory requirements. Trial approval was obtained from independent ethics committees or institutional review boards of participating sites. All patients provided written informed consent. pathfinder 2 is a multicentre, multinational, open-label, phase III trial evaluating the safety, pharmacokinetics and efficacy of N8-GP when used for the prophylaxis and treatment of bleeding episodes. It comprised a non-randomized main phase (completed and reported 14 ) and an ongoing two-part extension phase with both randomized and non-randomized patient cohorts ( Figure 1 ).
In the non-randomized main phase, patients received N8-GP prophylaxis as a single bolus dose of 50 IU/kg Q4D (twice-weekly dosing was permitted at the investigator's discretion). After the main phase, all patients were given the option of continuing treatment in the extension phase ( Figure 1 ).
Using the interactive voice/web-response system in extension phase part 1, a subset of eligible patients was randomized to receive 50 IU/kg Q4D (50Q4D) or 75 IU/kg Q7D (75Q7D) N8-GP prophylaxis Results: Fifty-five of 143 (38.5%) patients on prophylaxis who continued into the extension phase were randomized to receive 50 IU/kg Q4D (n = 17) or 75 IU/kg Q7D (n = 38). Nine patients in the Q7D cohort reverted to 50 IU/kg Q4D. No inhibitors were detected. In both cohorts, >50% of patients experienced no bleeds. Median ABR for overall, joint, spontaneous, traumatic and muscle was 0.00 for both cohorts.
Overall estimated success rate for treating bleeding episodes was 87.5%; 94.7% of bleeds were controlled with ≤2 injections.
Conclusions:
Weekly N8-GP was well tolerated and efficacious and may benefit selected "low bleeder" patients with haemophilia A.
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efficacy, FVIII, haemophilia A, N8-GP, once-weekly prophylaxis, safety for 24 weeks. Patients who experienced ≥3 bleeds during the preceding 6 months, and those unwilling to be randomized, continued to receive N8-GP prophylaxis at 50Q4D (non-randomized patients).
Randomized patients allocated to 75Q7D could revert to 50Q4D at any time at the investigator's discretion. In addition, any patient receiving N8-GP prophylaxis Q7D was required to revert to Q4D if ≥2 spontaneous or one severe bleeding episode requiring hospitalization occurred over an 8-week period.
Any bleeding episode was treated with N8-GP 20-75 IU/kg, depending on the severity and location of the bleed.
| Patients
Male patients aged ≥12 years with severe haemophilia A (FVIII <1%), a history of ≥150 exposure days to FVIII and without a history of FVIII inhibitors (≥0.6 Bethesda Units [BU]), were eligible for inclusion in pathfinder 2. For randomization eligibility in the extension phase, patients must have experienced ≤2 bleeds (spontaneous or traumatic) during the preceding 6 months of the main trial phase and be willing to undergo randomization.
| Objectives and endpoints
The coprimary objectives were to evaluate the immunogenicity of N8-GP and assess its clinical efficacy when used for once-weekly prophylaxis. These primary endpoints were, respectively, incidence of FVIII inhibitors (≥0.6 BU) and ABR. 
| Analytical methods and statistical analysis
See Appendix S1.
| RE SULTS

| Patients
Of 175 patients initially enrolled into pathfinder 2 and allocated to receive prophylaxis with N8-GP 50Q4D, 14 143 continued into the extension phase ( Figure 1) ; 120 met the randomization inclusion criteria, of which 55 received N8-GP prophylaxis at 50Q4D (n = 17) or 75Q7D (n = 38). The remaining 88 continued to receive 50Q4D in the non-randomized treatment cohort ( Figure 1 ). Of the 120 patients who fulfilled the randomization criteria, 65 (54%) preferred to stay on their treatment regimen. Randomized patient demographics and baseline characteristics are shown in Table 1 .
One patient from each of the randomized prophylaxis cohorts was withdrawn from the trial at the investigator's discretion, due
to SAEs considered unlikely to be related to N8-GP ( Figure 1 ): one hepatocellular carcinoma (50Q4D) and one ankle fracture (75Q7D).
There were nine other withdrawals from the 75Q7D cohort (23.7%) due to bleeding episodes (n = 8) or for safety reasons (n = 1; X-ray changes showing worsened pre-existent arthropathy). These nine reverted to the 50Q4D regimen (non-randomized treatment) due to the predefined safety criteria in the trial protocol. Patients withdrawn from randomization due to bleeding episodes were equally distributed over time, within first (n = 2), second (n = 2) and third month (n = 2) and after 5 months (n = 2). The patients who switched from the randomized 75Q7D to the non-randomized 50Q4D cohort (n = 8) remained "low bleeders" throughout the remaining treatment period.
In total, 16 and 28 patients in the 50Q4D and 75Q7D cohorts, respectively, completed the randomized treatment period of the extension phase ( Figure 1 ). Overall, there were 1539 exposure days to N8-GP in the randomized treatment period ( Table 2 ). antibodies at the end of the extension phase part 1 (50Q4D: n = 1;
| Safety
75Q7D: n = 2); one from each cohort remained positive at the last reported visit. A further three (50Q4D: n = 1; 75Q7D: n = 2) had one or two positive samples for low-titre anti-PEG antibodies during the extension phase. In all, no patients with anti-PEG antibodies reported AEs such as itching and rash. One patient reported eczema that was considered as a medical event of special interest not related to N8-GP.
FVIII activity did not differ between patients with or without anti-PEG antibodies.
| Prophylaxis
The proportion of patients who experienced no bleeding episodes while receiving N8-GP prophylaxis was 52.9% (9/17) In all, 13 bleeding episodes occurred in eight patients randomized to 50Q4D; 25 occurred in 16 patients in the 75Q7D cohort (Table 3 ).
In both cohorts, all bleeding episodes were mild or moderate, and as in the main phase, 14 most were spontaneous (50Q4D: 53.8% [7/13 bleeds]; 75Q7D: 64.0% [16/25 bleeds]) ( Figure 2 ). For the 50Q4D cohort, all bleeds were distributed throughout the 4-day dosing interval, with most occurring between days 2 and 4 (8/13 bleeds: 61.5%); while for the 75Q7D cohort, most bleeds occurred on days 6 and 7, since the last N8-GP dose (20/25 bleeds: 80.0%) ( Figure 3 ).
Joints were the most common bleed location for patients on the 50Q4D regimen (53.8% [7/13 bleeds; estimated mean ABR: 0.89; median ABR: 0.00]) ( Figure 2 ) and those on 75Q7D (68.0% [17/25 bleeds; estimated mean ABR: 2.78; median ABR: 0.00]). Other bleed locations in the 50Q4D cohort were muscle or subcutaneous (4/13 bleeds, 30.8%) and mucosal or "other" (2/13 bleeds, 15.4%). In the 75Q7D cohort, all other bleeding episodes were muscular (5/25 bleeds, 20.0%) or subcutaneous (3/25 bleeds, 12.0%) (see Table S1 ).
| Treatment of bleeding episodes
All treatment of bleeding episodes in the 50Q4D cohort (100%) and 80% in the 75Q7D cohort were considered a success (Table 4) 
| N8-GP consumption
In the 50Q4D and 75Q7D cohorts, respective median (range) N8-GP dose from bleed start to stop was 52. 
| FVIII activity
FVIII plasma activity was measured using a chromogenic assay (see Appendix S1). Mean peak FVIII activity levels (assessed 30 minutes postdosing) were similar before (1.33 IU/mL) and after (1.36 IU/ mL) randomization for the 50Q4D cohort, while mean peak levels for the 75Q7D cohort increased from 1.40 IU/mL before randomi- 
| CON CLUS IONS
The main finding of this extension trial is that effective prophylaxis was demonstrated at 75Q7D in patients with a low bleeding phenotype (≤2 bleeds during the preceding 6 months of the trial's main phase with a dosing regimen of 50Q4D). Importantly, 58% of patients on the 75Q7D regimen experienced no bleeding episodes during the 24-week randomization period, which was a similar percentage to patients in the 50Q4D (53%) dosing regimen.
Observed median ABR for overall, joint, spontaneous, traumatic and muscle was 0.00 for both cohorts. No correlation between predose FVIII activity and ABR was seen; the aetiology of bleeding in patients with haemophilia is multifactorial, and additional observations will be required to understand fully the ideal dosing regimen for most patients. These observations suggest that N8-GP at 75Q7D overall, estimated success rate for treating bleeding episodes was 87.5%, similar to the haemostatic success rate reported for the trial's main phase (84.2%). 14 The proportion of bleeding episodes successfully treated with ≤2 injections was similar between the main (95.5%) 14 and extension (94.7%) phases. As expected, overall N8-GP consumption was lower in 75Q7D (up to 650 IU/kg/y less) than the 50Q4D cohort, thereby reducing the treatment burden for patients with severe haemophilia A. Additionally, patients in the 75Q7D cohort received fewer annual injections (52.0 injections/y) to maintain adequate plasma FVIII activity levels when compared to patients on standard FVIII products (~182 injections/y), 1, 7, 8 which is mainly attributed to the EHL property of N8-GP.
Promising results have also been achieved in recent studies of other EHL products. [15] [16] [17] 20 To date, Q7D dosing with an EHL product has been assessed in two other phase III trials. 15, 20 A partially randomized trial of rFVIII Fc fusion protein (rFVIIIFc) randomized 47 adult and adolescent patients, who had received only ondemand treatment prior to trial entry, to receive either on-demand rFVIIIFc treatment or weekly rFVIIIFc prophylaxis (65 IU/kg Q7D). 15 Observed median ABR in the 23 patients who received weekly rFVIIIFc prophylaxis was 3.6. The proportion who experienced no bleeding episodes while on rFVIIIFc prophylaxis Q7D was 17.4%; three (13%) experienced >5 bleeding episodes. 15 [15] [16] [17] suggest that reducing the treatment burden for patients with severe haemophilia A is a realistic and achievable goal for selected cohorts. 4, 7 In conclusion, data from the randomized part of the extension The estimated success rate that is rated "excellent" or "good"; the planned analysis was based on cumulative. Analysed using logistic regression accounting for repeated measures within patient assuming compound symmetry working correlation. Missing responses are counted as failure.
patients receiving this regimen experienced no bleeding episodes during the 24-week extension period. These findings suggest that weekly N8-GP may provide effective prophylaxis with a reduced treatment burden for a selected subset of low-bleeding patients with severe haemophilia A. 
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